

PLEASE CLICK ON THE PAGE NUMBER TO MOVE TO THE RELEVANT PAGE.

KEY HIGHLIGHTS

Update

China Sunshin Chemical (CSSC SP/BUY/\$0.395/Target: \$0.46)

Compressed margins amid intensified competition.

Page 2

TRADERS' CORNER

SATS (SATS SP): Trading BUY

Keppel Corp (KEP SP): Trading BUY

Page 5

KEY INDICES

	Prev Close	1D %	1W %	1M %	YTD %
DJIA	37090.2	1.4	2.9	8.0	11.9
S&P 500	4707.1	1.4	3.5	6.7	22.6
FTSE 100	7548.4	0.1	0.4	1.7	1.3
AS30	7469.1	0.3	1.1	3.6	3.4
CSI 300	3369.6	(1.7)	(0.9)	(5.9)	(13.0)
FSSTI	3104.3	0.1	0.6	(0.0)	(4.5)
HSCEI	5550.9	(1.1)	(2.0)	(6.9)	(17.2)
HSI	16228.8	(0.9)	(1.4)	(6.7)	(18.0)
JCI	7075.3	(0.7)	(0.2)	3.1	3.3
KLCI	1448.0	0.1	0.2	(0.3)	(3.2)
KOSPI	2510.7	(1.0)	0.6	3.2	12.3
Nikkei 225	32926.4	0.3	(1.6)	0.7	26.2
SET	1358.0	(1.2)	(1.8)	(2.0)	(18.6)
TWSE	17468.9	0.1	0.6	3.3	23.6
BDI	2438	(4.4)	(14.4)	47.3	60.9
CPO (RM/mt)	3653	0.0	(0.0)	(0.5)	(9.8)
Brent Crude (US\$/bbl)	75	1.9	0.5	(9.5)	(13.1)

Source: Bloomberg

TOP TRADING TURNOVER

Company	Price (\$)	Chg (%)	5-day ADT (\$m)
DBS Group Holdings	31.82	0.8	117.4
Oversea-Chinese Banking Corp	12.51	0.1	54.7
United Overseas Bank	27.77	0.3	54.2
Genting Singapore	0.99	0.0	44.5
Singapore Telecommunications	2.38	0.8	41.7

TOP GAINERS

Company	Price (\$)	Chg (%)	5-day ADT (\$m)
Top Glove Corp	0.26	10.9	0.8
CapitaLand India Trust	1.14	2.7	5.0
Propnex	0.85	1.2	0.1
Emperador Inc	0.52	1.0	0.6
Raffles Medical Group	1.07	0.9	1.1

TOP LOSERS

Company	Price (\$)	Chg (%)	5-day ADT (\$m)
Nio Inc-Class A	7.30	(4.6)	1.5
Mandarin Oriental -Jers Reg	1.53	(3.2)	0.1
Seatrium	0.11	(2.8)	29.1
Parkwaylife Real Estate	3.47	(2.5)	1.4
Oue Commercial Real Estate	0.28	(1.8)	1.3

*ADT: Average daily turnover

KEY ASSUMPTIONS

GDP (% yoy)	2022	2023F	2024F
US	1.9	2.4	1.0
Euro Zone	3.5	0.5	0.6
Japan	0.9	1.5	1.0
Singapore	3.6	0.9	2.9
Malaysia	8.7	4.0	4.6
Thailand	2.6	2.3	3.6
Indonesia	5.3	5.1	5.2
Hong Kong	-3.5	4.6	3.0
China	3.0	5.0	4.6
CPO (RM/mt)	5,088	4,000	4,200
Brent (Average) (US\$/bbl)	99.0	81.0	84.0

Source: Bloomberg, UOB ETR, UOB Kay Hian

COMPANY UPDATE

China SunSine Chemical (CSSC SP)

Compressed Margins Amid Intensified Competition

Sunsine provided a 3Q23 update, reporting a record-high quarterly sales volume (+16.3% yoy). However, lower ASPs and a flexible pricing strategy led to lower 3Q23 sales (-5% yoy). 3Q23 net profit fell 49% yoy, taking 9M23 net profit to Rmb259.6m and missing our forecast. While domestic vehicle sales continue to improve, in the face of stronger competition, we have lowered earnings expectations for 2023-25. Maintain BUY with a 20% lower target price of S\$0.460 (from S\$0.575).

WHAT'S NEW

- Margins below expectations.** China SunSine Chemical (Sunsine) reported 3Q23 revenue of Rmb875m (-5% yoy), mainly due to lower average selling prices of rubber accelerators and its newly-adopted flexible pricing strategy. This was partially mitigated by record-high quarterly sales volume of 56,114 tonnes (+16.3% yoy), from the more flexible pricing strategy implemented to remain competitive in the Chinese rubber chemicals industry. Overall, SunSine's net profit came in at Rmb65m (-49.2% yoy), bringing 9M23 net profit to Rmb259.6m and making up 53% of our full-year estimate.
- Potential near-term benefit from higher ASPs of rubber accelerators.** Per Sublime China Information (SCI), the ASPs of rubber accelerators, the main earnings driver for SunSine, have risen by approximately 36.7% from end-2Q23 to end-3Q23. The rise is in tandem with higher average prices of aniline, the major feedstock for rubber accelerators, which has gained an estimated 33.7% to Rmb13,900/tonne in the same period. This may signal better 4Q23 margins from higher ASPs. To recap, SunSine adopts quarterly pricing for its major customers, leading to an estimated one quarter pricing time-lag in raw material price changes.
- Higher vehicle sales a positive for SunSine.** China's auto sales have risen 8.2% yoy to 21.1m units as at end-9M23, while New Energy Vehicle sales increased 37.5% yoy to 6.3m units in the same period. Overall production utilisation rate of Chinese tyre manufacturing companies has also improved in 3Q23. This demonstrates the recovery of China's economy, which has grown 5.2% yoy in GDP. We believe SunSine's capacity utilisation rate is poised to improve in line with the growth in vehicle sales. To recap, the capacity utilisation rate for rubber accelerators was 80% as at end-1H23.
- Continuous expansion projects undertaken.** Phase 1 of a high-quality intermediate material project of 20,000 tonnes/year capacity is expected to commence production in early-24, while Phase 2 of an insoluble sulphur project of 30,000 tonnes/year capacity is expected to begin in 1H24. These projects will increase capacity and are likely to lift sales volume when operational.

KEY FINANCIALS

Year to 31 Dec (Rmbm)	2021	2022	2023F	2024F	2025F
Net turnover	3,725	3,825	3,455	3,730	3,913
EBITDA	829	897	542	623	674
Operating profit	699	734	372	445	489
Net profit (rep./act.)	506	642	324	388	426
Net profit (adj.)	542	606	324	388	426
EPS (Fen)	55.9	62.8	33.5	40.1	44.1
PE (x)	3.8	3.4	6.3	5.3	4.8
P/B (x)	0.6	0.6	0.5	0.5	0.5
EV/EBITDA (x)	0.9	0.8	1.3	1.2	1.1
Dividend yield (%)	4.8	5.8	3.0	3.5	4.1
Net margin (%)	13.6	16.8	9.4	10.4	10.9
Net debt/(cash) to equity (%)	(43.4)	(37.0)	(33.9)	(30.4)	(32.6)
Interest cover (x)	n.a.	n.a.	n.a.	n.a.	n.a.
ROE (%)	17.2	18.7	8.6	9.7	9.9
Consensus net profit	-	-	321	363	408
UOBKH/Consensus (x)	-	-	1.01	1.07	1.04

Source: SunSine, Bloomberg, UOB Kay Hian

BUY

(Maintained)

Share Price	S\$0.395
Target Price	S\$0.460
Upside	+16.5%
(Previous TP:	S\$0.575)

COMPANY DESCRIPTION

Sunsine produces rubber chemicals, primarily rubber accelerators and other related rubber chemicals such as anti-scorching agents.

STOCK DATA

GICS sector	Materials
Bloomberg ticker:	CSSC SP
Shares issued (m):	959.7
Market cap (S\$ m):	379.1
Market cap (US\$m):	282.1
3-mth avg daily t'over (US\$m):	0.0


Price Performance (%)

52-week high/low	S\$ 0.467/S\$ 0.370			
1mth	3mth	6mth	1yr	YTD
1.3	1.3	(6.0)	1.2	(3.6)

Major Shareholders

Xu Cheng Qiu	61.4%
FY23 NAV/Share (Rmb)	3.98
FY23 Net Cash/Share (Rmb)	1.35

PRICE CHART



Source: Bloomberg

ANALYST(S)

Heidi Mo
 +65 6590 6630
 heidimo@uobkayhian.com

John Cheong
 +65 6590 6623
 johncheong@uobkayhian.com

STOCK IMPACT

- **Maintaining market leadership and strong balance sheet.** As of end-1H23, management reported that Sunsine remains the top accelerator producer globally, and top insoluble sulphur producer in China. Based on their estimates, the company also leads the domestic market with 33% share for rubber accelerators in 2022. Additionally, total cash and bank balances stood at Rmb1,475.2m with no debt outstanding, which equates to Rmb1.54/share (S\$0.29/share) as at end-1H23. Together with its flexible pricing strategy and capacity expansion plans, Sunsine is likely to remain competitive against its peers.

EARNINGS REVISION/RISK

- **We have tweaked our 2023-25 gross margin assumptions from 29% to 23-24%** over the period, on account of price adjustments in the face of competitive pressures in the industry. Correspondingly, we have lowered our 2023/24/25 earnings estimates by 34%/33%/27% to Rmb324m/Rmb388m/Rmb426m respectively.

VALUATION/RECOMMENDATION

- **Maintain BUY with a 20% lower target price of S\$0.460 (S\$0.575 previously)**, pegged to a multiple of 6x 2024F PE, its long-term average mean. We have rolled our valuation base year to 2024.

SHARE PRICE CATALYST


- Production commencement for new capacities.
- Higher ASPs for rubber chemicals.
- Higher-than-expected utilisation rates.

PEER COMPARISON

Company	Ticker	Trading Curr (lcy)	Price @ 11-Dec-23 (lcy)	Market Cap (US\$m)	PE		P/B		EV/EBITDA		ROE 2023 (%)	Yield 2023 (%)	Net Gearing (%)
					2023 (x)	2024 (x)	2023 (x)	2024 (x)	2023 (x)	2024 (x)			
China Sunsine	CSSC SP	S\$	0.395	282	4.4	3.8	0.5	0.5	0.8	0.7	12.0	4.3	(39.3)
Shandong Yanggu Huatai	300121 CH	CNY	8.96	511	8.7	6.9	1.2	1.0	4.6	3.8	12.7	2.8	(1.6)
Lanxess AG	LXS GR	EUR	26.14	2,431	n.a.	16.9	0.5	0.5	9.3	6.9	9.5	1.1	42.3
Eastman Chemical	EMN US	USD	84.85	10,060	13.3	10.8	1.8	1.7	9.3	8.2	14.0	3.7	88.1
Arkema SA	AKE FP	EUR	91.64	7,408	10.6	9.3	0.9	0.9	5.8	5.3	8.9	3.8	23.1
Global average					10.9	11.0	1.1	1.0	7.2	6.1	11.2	2.8	38.0


Source: Bloomberg, UOB Kay Hian

ASP FOR RUBBER ACCELERATORS (RA)



Source: China Sunsine, UOB Kay Hian

ASP FOR ANILINE



Source: China Sunsine, UOB Kay Hian

PROFIT & LOSS

Year to 31 Dec (Rmbm)	2022	2023F	2024F	2025F
Net turnover	3,825.0	3,454.8	3,730.4	3,912.7
EBITDA	897.1	542.3	622.8	673.9
Deprec. & amort.	163.4	170.1	177.4	184.6
EBIT	733.7	372.2	445.4	489.3
Associate contributions	0.0	0.0	0.0	0.0
Net interest income/(expense)	0.0	0.0	0.0	0.0
Pre-tax profit	733.7	372.2	445.4	489.3
Tax	(91.3)	(48.4)	(57.9)	(63.6)
Minorities	0.0	0.0	0.0	0.0
Net profit	642.4	323.8	387.5	425.7
Net profit (adj.)	606.3	323.8	387.5	425.7

CASH FLOW

Year to 31 Dec (Rmbm)	2022	2023F	2024F	2025F
Operating	207.5	195.2	125.0	376.2
Pre-tax profit	733.7	372.2	445.4	489.3
Tax	(53.6)	(117.5)	(42.6)	(54.4)
Deprec. & amort.	159.6	166.6	173.7	180.7
Working capital changes	(631.5)	(226.1)	(451.6)	(239.4)
Non-cash items	(0.7)	0.0	0.0	0.0
Investing	(141.0)	(81.6)	(81.3)	(81.1)
Capex (growth)	(85.2)	(85.0)	(85.0)	(85.0)
Proceeds from sale of assets	0.1	0.0	0.0	0.0
Others	(55.9)	3.4	3.7	3.9
Financing	(121.5)	(175.2)	(86.8)	(97.2)
Dividend payments	(123.1)	(175.2)	(86.8)	(97.2)
Issue of shares	0.0	0.0	0.0	0.0
Loan repayment	0.0	0.0	0.0	0.0
Others/interest paid	1.6	0.0	0.0	0.0
Net cash inflow (outflow)	(55.0)	(61.5)	(43.1)	197.9
Beginning cash & cash equivalent	1,377.3	1,364.9	1,303.4	1,260.3
Changes due to forex impact	42.6	0.0	0.0	0.0
Ending cash & cash equivalent	1,364.9	1,303.4	1,260.3	1,458.2


BALANCE SHEET

Year to 31 Dec (Rmbm)	2022	2023F	2024F	2025F
Fixed assets	861.7	780.1	691.4	595.6
Other LT assets	213.0	209.6	205.9	202.0
Cash/ST investment	1,364.9	1,303.4	1,260.3	1,458.2
Other current assets	1,784.9	1,865.6	2,126.3	2,347.6
Total assets	4,224.5	4,158.6	4,283.9	4,603.5
ST debt	0.0	0.0	0.0	0.0
Other current liabilities	532.7	318.2	142.7	133.8
LT debt	0.0	0.0	0.0	0.0
Other LT liabilities	0.0	0.0	0.0	0.0
Shareholders' equity	3,691.8	3,840.5	4,141.2	4,469.7
Minority interest	0.0	0.0	0.0	0.0
Total liabilities & equity	4,224.5	4,158.6	4,283.9	4,603.5

KEY METRICS

Year to 31 Dec (%)	2022	2023F	2024F	2025F
Profitability				
EBITDA margin	23.5	15.7	16.7	17.2
Pre-tax margin	19.2	10.8	11.9	12.5
Net margin	16.8	9.4	10.4	10.9
ROA	15.8	7.7	9.2	9.6
ROE	18.7	8.6	9.7	9.9
Growth				
Turnover	2.7	(9.7)	8.0	4.9
EBITDA	8.2	(39.6)	14.9	8.2
Pre-tax profit	4.9	(49.3)	19.7	9.8
Net profit	26.9	(49.6)	19.7	9.8
Net profit (adj.)	11.8	(46.6)	19.7	9.8
EPS	12.3	(46.6)	19.7	9.8
Leverage				
Debt to total capital	0.0	0.0	0.0	0.0
Debt to equity	0.0	0.0	0.0	0.0
Net debt/(cash) to equity	(37.0)	(33.9)	(30.4)	(32.6)
Interest cover (x)	n.a.	n.a.	n.a.	n.a.

TRADERS' CORNER



SATS (SATS SP)

Trading Buy Range: S\$2.68-2.69
 Last price: S\$2.69
 Target price: S\$2.96
 Protective stop: S\$2.60

The chart outlook is bullish as price is trading above the cloud. Conversion and base lines remain in a bullish crossover. The MACD remains bullish with both of its lines above the zero line. These could increase chances of the stock price moving higher.

We see increasing odds of stock price testing S\$2.96. Stop-loss could be placed at S\$2.60.

Approximate timeframe on average: 1-2 weeks (initiate this trade idea if the stock hits the entry price range within three trading days)

Our institutional research has a fundamental BUY and target price of S\$2.90.



Keppel Corp (KEP SP)

Trading Buy Range: S\$6.75-6.76
 Last price: S\$6.76
 Target price: S\$7.42
 Protective stop: S\$6.57

Price is trading above the cloud, keeping the uptrend intact. Conversion and base lines remain in a bullish crossover and the conversion line is moving higher. The MACD remains bullish. These could increase chances of the stock price moving higher.

We see increasing odds of stock price testing S\$7.42. Stop-loss could be placed at S\$6.57.

Approximate timeframe on average: 1-2 weeks (initiate this trade idea if the stock hits the entry price range within three trading days)

Our institutional research has a fundamental BUY and target price of S\$9.09.

ANALYST(S)

Wong Shueh Ting, CFTe
 +65 6590 6616
 shuehting@uobkayhian.com

Disclosures/Disclaimers

This report is prepared by UOB Kay Hian Private Limited ("UOBKH"), which is a holder of a capital markets services licence and an exempt financial adviser in Singapore.

This report is provided for information only and is not an offer or a solicitation to deal in securities or to enter into any legal relations, nor an advice or a recommendation with respect to such securities.

This report is prepared for general circulation. It does not have regard to the specific investment objectives, financial situation and the particular needs of any recipient hereof. Advice should be sought from a financial adviser regarding the suitability of the investment product, taking into account the specific investment objectives, financial situation or particular needs of any person in receipt of the recommendation, before the person makes a commitment to purchase the investment product.

This report is confidential. This report may not be published, circulated, reproduced or distributed in whole or in part by any recipient of this report to any other person without the prior written consent of UOBKH. This report is not directed to or intended for distribution to or use by any person or any entity who is a citizen or resident of or located in any locality, state, country or any other jurisdiction as UOBKH may determine in its absolute discretion, where the distribution, publication, availability or use of this report would be contrary to applicable law or would subject UOBKH and its connected persons (as defined in the Financial Advisers Act, Chapter 110 of Singapore) to any registration, licensing or other requirements within such jurisdiction.

The information or views in the report ("Information") has been obtained or derived from sources believed by UOBKH to be reliable. However, UOBKH makes no representation as to the accuracy or completeness of such sources or the Information and UOBKH accepts no liability whatsoever for any loss or damage arising from the use of or reliance on the Information. UOBKH and its connected persons may have issued other reports expressing views different from the Information and all views expressed in all reports of UOBKH and its connected persons are subject to change without notice. UOBKH reserves the right to act upon or use the Information at any time, including before its publication herein.

Except as otherwise indicated below, (1) UOBKH, its connected persons and its officers, employees and representatives may, to the extent permitted by law, transact with, perform or provide broking, underwriting, corporate finance-related or other services for or solicit business from, the subject corporation(s) referred to in this report; (2) UOBKH, its connected persons and its officers, employees and representatives may also, to the extent permitted by law, transact with, perform or provide broking or other services for or solicit business from, other persons in respect of dealings in the securities referred to in this report or other investments related thereto; (3) the officers, employees and representatives of UOBKH may also serve on the board of directors or in trustee positions with the subject corporation(s) referred to in this report. (All of the foregoing is hereafter referred to as the "Subject Business"); and (4) UOBKH may otherwise have an interest (including a proprietary interest) in the subject corporation(s) referred to in this report.

As of the date of this report, no analyst responsible for any of the content in this report has any proprietary position or material interest in the securities of the corporation(s) which are referred to in the content they respectively author or are otherwise responsible for.

IMPORTANT DISCLOSURES FOR U.S. PERSONS

This research report was prepared by UOBKH, a company authorized, as noted above, to engage in securities activities in Singapore. UOBKH is not a registered broker-dealer in the United States and, therefore, is not subject to U.S. rules regarding the preparation of research reports and the independence of research analysts. This research report is provided for distribution by UOBKH (whether directly or through its US registered broker dealer affiliate named below) to "major U.S. institutional investors" in reliance on the exemption from registration provided by Rule 15a-6 of the U.S. Securities Exchange Act of 1934, as amended (the "Exchange Act"). All US persons that receive this document by way of distribution from or which they regard as being from UOBKH by their acceptance thereof represent and agree that they are a major institutional investor and understand the risks involved in executing transactions in securities.

Any U.S. recipient of this research report wishing to effect any transaction to buy or sell securities or related financial instruments based on the information provided in this research report should do so only through UOB Kay Hian (U.S.) Inc ("UOBKHUS"), a registered broker-dealer in the United States. Under no circumstances should any recipient of this research report effect any transaction to buy or sell securities or related financial instruments through UOBKH.

UOBKHUS accepts responsibility for the contents of this research report, subject to the terms set out below, to the extent that it is delivered to and intended to be received by a U.S. person other than a major U.S. institutional investor.

The analyst whose name appears in this research report is not registered or qualified as a research analyst with the Financial Industry Regulatory Authority ("FINRA") and may not be an associated person of UOBKHUS and, therefore, may not be subject to applicable restrictions under FINRA Rules on communications with a subject company, public appearances and trading securities held by a research analyst account.

Analyst Certification/Regulation AC

Each research analyst of UOBKH who produced this report hereby certifies that (1) the views expressed in this report accurately reflect his/her personal views about all of the subject corporation(s) and securities in this report; (2) the report was produced independently by him/her; (3) he/she does not carry out, whether for himself/herself or on behalf of UOBKH or any other person, any of the Subject Business involving any of the subject corporation(s) or securities referred to in this report; and (4) he/she has not received and will not receive any compensation that is directly or indirectly related or linked to the recommendations or views expressed in this report or to any sales, trading, dealing or corporate finance advisory services or transaction in respect of the securities in this report. However, the compensation received by each such research analyst is based upon various factors, including UOBKH's total revenues, a portion of which are generated from UOBKH's business of dealing in securities.

Reports are distributed in the respective countries by the respective entities and are subject to the additional restrictions listed in the following table.

General	This report is not intended for distribution, publication to or use by any person or entity who is a citizen or resident of or located in any country or jurisdiction where the distribution, publication or use of this report would be contrary to applicable law or regulation.
Hong Kong	This report is distributed in Hong Kong by UOB Kay Hian (Hong Kong) Limited ("UOBKHHK"), which is regulated by the Securities and Futures Commission of Hong Kong. Neither the analyst(s) preparing this report nor his associate, has trading and financial interest and relevant relationship specified under Para. 16.4 of Code of Conduct in the listed corporation covered in this report. UOBKHHK does not have financial interests and business relationship specified under Para. 16.5 of Code of Conduct with the listed corporation covered in this report. Where the report is distributed in Hong Kong and contains research analyses or reports from a foreign research house, please note: (i) recipients of the analyses or reports are to contact UOBKHHK (and not the relevant foreign research house) in Hong Kong in respect of any matters arising from, or in connection with, the analysis or report; and (ii) to the extent that the analyses or reports are delivered to and intended to be received by any person in Hong Kong who is not a professional investor, or institutional investor, UOBKHHK accepts legal responsibility for the contents of the analyses or reports only to the extent required by law.
Indonesia	This report is distributed in Indonesia by PT UOB Kay Hian Sekuritas, which is regulated by Financial Services Authority of Indonesia ("OJK"). Where the report is distributed in Indonesia and contains research analyses or reports from a foreign research house, please note recipients of the analyses or reports are to contact PT UOBKH (and not the relevant foreign research house) in Indonesia in respect of any matters arising from, or in connection with, the analysis or report.
Malaysia	Where the report is distributed in Malaysia and contains research analyses or reports from a foreign research house, the recipients of the analyses or reports are to contact UOBKHM (and not the relevant foreign research house) in Malaysia, at +603-21471988, in respect of any matters arising from, or in connection with, the analysis or report as UOBKHM is the registered person under CMSA to distribute any research analyses in Malaysia.
Singapore	This report is distributed in Singapore by UOB Kay Hian Private Limited ("UOBKH"), which is a holder of a capital markets services licence and an exempt financial adviser regulated by the Monetary Authority of Singapore. Where the report is distributed in Singapore and contains research analyses or reports from a foreign research house, please note: (i) recipients of the analyses or reports are to contact UOBKH (and not the relevant foreign research house) in Singapore in respect of any matters arising from, or in connection with, the analysis or report; and (ii) to the extent that the analyses or reports are delivered to and intended to be received by any person in Singapore who is not an accredited investor, expert investor or institutional investor, UOBKH accepts legal responsibility for the contents of the analyses or reports only to the extent required by law.
Thailand	This report is distributed in Thailand by UOB Kay Hian Securities (Thailand) Public Company Limited, which is regulated by the Securities and Exchange Commission of Thailand.
United Kingdom	This report is being distributed in the UK by UOB Kay Hian (U.K.) Limited, which is an authorised person in the meaning of the Financial Services and Markets Act and is regulated by The Financial Conduct Authority. Research distributed in the UK is intended only for institutional clients.
United States of America ('U.S.')	This report cannot be distributed into the U.S. or to any U.S. person or entity except in compliance with applicable U.S. laws and regulations. It is being distributed in the U.S. by UOB Kay Hian (US) Inc, which accepts responsibility for its contents. Any U.S. person or entity receiving this report and wishing to effect transactions in any securities referred to in the report should contact UOB Kay Hian (US) Inc. directly.

Copyright 2023, UOB Kay Hian Pte Ltd. All rights reserved.

<http://research.uobkayhian.com>

RCB Regn. No. 197000447W